Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5534)	1/24/2002 1:39:10 PM
From: Biomaven	Respond to of 52153

Some evidence today that the FDA's not entirely on vacation - an approval and an approvable, both in 10 months. FRX got an approvable letter for their single isomer version of Celexa (licensed from Lundbeck), and ATRX got an approval for their leuprolide one-month depot for prostate cancer. Peter

To: Biomaven who wrote (5534)	1/24/2002 1:40:21 PM
From: scott_jiminez	Read Replies (2) \| Respond to of 52153

It's not a question of deceit. There are dozens of BTs willing to publish on a timeline exactly equivalent to academia. Other BTs feel the world is a vast conspiracy with hoards of competitors awaiting each morsel of revelation from their peers. When I followed Ariad I had the impression they were among the elite of the former group, publishing many articles per year (including, invariably, some in Science/Nature/Cell). One need not put up with 'public claims'; peer-reviewed disclosure is not the gold-standard. It's the only standard. Blithely, blatherly and condescendingly yours, Scott.